Cephalexin

Quick links to important sections

Cephalexin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cephalexin

Property Description
Active ingredient Cephalexin (INN)
Form Capsule, Tablet, Oral Suspension
Pharmacological class First-generation Cephalosporin Antibiotic
Common use Eradicating susceptible bacterial infections
Origin Semisynthetic

Cephalexin, also known by the name Cefalexin, is a widely recognized, semisynthetic beta-lactam antibiotic prescribed exclusively to treat infections caused by susceptible bacteria. It is a single-ingredient drug classified as a first-generation cephalosporin and is utilized as an effective oral agent. This compound is distinctive because it is inherently acid-stable, a feature crucial for ensuring reliable absorption after being taken by mouth.


Classification and Purpose

Cephalexin belongs to the cephalosporin antibiotics family, functioning as a potent bactericidal agent—meaning it actively kills the targeted bacterial pathogens. Its classification as a first-generation antibiotic means it is specifically valued for its strong activity against many common gram-positive organisms. This profile is often employed in scenarios where a trusted, orally administered agent is required to resolve an infection caused by a susceptible bacterial strain. For example, it is frequently utilized as a standard therapeutic choice for certain skin structure infections.

The fundamental therapeutic purpose of Cephalexin is to provide a decisive intervention that eradicates bacterial infections. Its direct, lytic action ensures the effective destruction of the pathogen, which reinforces its role in terminating the infection. Its consistent inclusion on the World Health Organization's List of Essential Medicines further reflects its clinical importance in foundational medicine.

What side effects are possible with Cephalexin?

Possible Side Effects and Safety Information

Cephalexin's safety profile is categorized by regulatory authorities based on the frequency of documented adverse reactions and the physiological systems affected. The majority of reported effects fall within the Common or Uncommon classifications.


Adverse Reaction Classifications

Side effects are primarily grouped by System-Organ Classes (SOC) in official labeling. The most frequent events are linked to Gastrointestinal Disorders (e.g., diarrhea, nausea) and Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus).

Frequency Category (Regulatory Aligned) Examples of Documented Adverse Reactions
Common Diarrhea, Nausea, Rash
Uncommon Eosinophilia, Transient hepatic enzyme elevation
Rare Reversible interstitial nephritis, Hemolytic anemia, Vomiting

Serious Adverse Reactions

Specific reactions, though rare, are highlighted in regulatory documents due to their potential clinical significance. These include severe immune responses such as Anaphylaxis and severe cutaneous adverse reactions like Stevens-Johnson Syndrome.

Also documented is the risk of Pseudomembranous Colitis (or Clostridium difficile-associated diarrhea), which can occur during or after the cessation of antibacterial treatment. Cephalosporins have also been associated with the potential for seizures in certain circumstances, particularly when renal function is impaired.


Population-Specific Safety Considerations

The official label requires specific caution for individuals with renal impairment, as Cephalexin is eliminated primarily by the kidneys, necessitating careful observation. Safety notes also advise caution for patients with a documented history of colitis or other serious gastrointestinal disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosing on cephalexin requires immediate attention. If an overdosage is suspected, contact a Poison Control Center or seek emergency medical treatment immediately.

Symptoms of an oral overdose may include nausea, vomiting, epigastric distress (stomach pain), diarrhea, and hematuria (blood in the urine). A more serious presentation of overdose is a seizure, which may occur, particularly in patients who have impaired renal function.

Required Emergency Actions

For an overdose, a patient should be carefully observed and receive supportive therapy as clinically needed. The drug can be removed from the body by dialysis if necessary.

Immediate emergency measures are also required for any signs of a serious acute hypersensitivity reaction (e.g., hives, difficulty breathing, swelling of the face, lips, tongue, or throat) which can be life-threatening and may not be dose-related. In these circumstances, the drug should be discontinued immediately, and emergency medical help must be sought.

Therapeutic Uses of Cephalexin

What Cephalexin Treats: Main Uses and Benefits

Quick Facts

  • Therapeutic Domain: Addresses infections of the respiratory tract.
  • Common Use Cases: Manages certain ear infections (otitis media).
  • Additional Areas: Used in the care of certain bone and skin structure infections.
  • Key Action: Utilized in the management of genitourinary tract infections.

Cephalexin is a medication indicated for the management of certain bacterial infections in the body. Its therapeutic utility is focused on conditions caused by susceptible microorganisms, and it is not active against viral illnesses such as the common cold or influenza.

The medication is used to address respiratory tract infections and certain cases of otitis media (middle ear infection). It is also prescribed to assist in the resolution of infections affecting the skin and skin structure. Furthermore, Cephalexin serves as a treatment option in the care plan for bone infections and is utilized in the management of genitourinary tract infections, including acute prostatitis.

Using this medication helps to support the body’s recovery from these bacterial conditions. Treatment is reserved for conditions proven or strongly suspected to be caused by susceptible bacteria, a principle which helps to reduce the development of resistance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cephalexin?

This information is based strictly on governmental regulatory documents regarding eligibility for Cephalexin use and does not constitute medical advice.

Official Eligibility Summary

Classification Population/Condition Notes
Contraindicated Known allergy to Cephalexin or Cephalosporins Absolute prohibition due to hypersensitivity risk.
Caution/Restricted Markedly impaired Renal Function (Creatinine Clearance <30 mL/min) Use with caution; careful clinical observation and potential dose adjustment necessary.
Caution/Restricted Nursing Mothers Excreted in human milk; caution should be exercised.
Restricted (Age) Pediatric patients under 1 year of age Safety and effectiveness are not established for all indications in this group.
Caution (Age) Geriatric Patients Increased likelihood of decreased renal function requires careful dose selection.
Caution/Restricted Pregnant Women Category B; use is limited to situations where the drug is clearly needed.

Cephalexin is typically considered appropriate for use in adults and pediatric patients over one year of age whose renal function is not severely impaired. A prior history of a severe allergic reaction to penicillins or other beta-lactam drugs also requires careful evaluation by a healthcare provider due to the potential for cross-sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Cephalexin is primarily defined by its effects on renal transport and systemic exposure of co-administered medicines.

Documented Drug-Drug Interactions

Interacting Substance Official Regulatory Description of Interaction
Probenecid This substance inhibits the renal excretion of Cephalexin via tubular secretion. Co-administration results in increased and prolonged plasma concentrations of Cephalexin and is formally not recommended in regulatory labeling.
Metformin Co-administration results in a pharmacokinetic interaction that significantly increases the plasma Cmax and AUC (systemic exposure) of Metformin. This outcome is associated with a decrease in Metformin mean renal clearance.

Interaction with Products and Laboratory Tests

Cephalexin may cause a false-positive reaction for the presence of glucose in the urine when tests utilize Benedict's or Fehling's solutions or Clinitest tablets. This diagnostic interference must be noted when interpreting results from these specific assays.

Regarding administration timing, Cephalexin is acid stable and may be administered without regard to meals. No mandatory food-related separation rules are documented.

Population-Specific Interaction Caution

In patients with markedly impaired renal function, caution is advised due to the risk of delayed clearance of Cephalexin. This pharmacokinetic alteration necessitates closer observation concerning potential drug-drug interactions.

Mechanism of Action

Irreversible Inhibition of Cell Wall Assembly

Cephalexin acts as a suicide inhibitor by targeting essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). The molecule forms a stable, covalent bond with the active site of these transpeptidases, leading to their permanent inactivation. This mechanism specifically blocks the transpeptidation process—the final step required for the bacterial cell to cross-link and construct its structural peptidoglycan cell wall.


Bactericidal Cascade and Pathogen Destruction

The inability to finalize the cell wall results in a compromised structure that cannot withstand the organism's high internal fluid pressure. This structural failure causes the bacterial cell to rupture, a process known as lysis. This specific, lethal disruption of a fundamental bacterial process results in the active killing of susceptible, actively dividing organisms, leading to the destruction of the pathogenic bacterial population in the system.


Enzymatic Mechanism Limitations

The functional activity of this mechanism is constrained by bacterial resistance strategies, such as the production of beta-lactamase enzymes. These enzymes destroy the active portion of the Cephalexin molecule before it can bind to the PBP target, thereby preventing irreversible inhibition and maintaining the structural integrity of the bacterial wall.

Dosage and Administration Information

How Cephalexin is Used

Cephalexin is an antibiotic prescribed based on established guidelines for its oral administration. These guidelines define the approved routes, dosage forms, standard regimens, and necessary adjustments for use.


Official Administration Instructions

Feature Regulatory Instruction
Route of Administration Administered exclusively by the oral route (by mouth).
Available Forms Capsule (e.g., 250 mg, 500 mg), Tablet (e.g., 250 mg, 500 mg), and Oral Suspension (e.g., 125 mg/5 mL).
Timing in Relation to Meals Can be taken with or without food.
Standard Adult Dosing The typical range is 1 g to 4 g daily in divided doses. Common regimens include 250 mg every 6 hours (q6h) or 500 mg every 12 hours (q12h).
Course Duration Generally 7 to 14 days. For infections caused by beta-hemolytic streptococci, a minimum treatment duration of 10 days is required.

Key Use Adjustments

Official labeling provides specific instructions for certain populations to ensure proper drug levels are maintained:

  • Pediatric Dosing: Dosage is calculated based on body weight, typically 25 to 50 mg/kg/day in divided doses, though higher doses are used for specific conditions like otitis media.
  • Renal Impairment: The dose is reduced in patients with markedly impaired kidney function (renal impairment) to prevent accumulation of the medicine in the body, based on measured creatinine clearance.

Practical Administration Notes

The full prescribed course is intended to be completed to eradicate the infection and minimize resistance. If using the oral suspension, the liquid is shaken well before each dose and accurately measured with a calibrated device.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cephalexin


Evidence for Use in Skin and Skin Structure Infections (SSTIs)

The research for Cephalexin in conditions affecting the skin includes findings from Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers examined uncomplicated conditions in both adult and pediatric populations, detailing the measurement of clinical cure and microbiological cure. Research so far was studied for its role in contexts associated with these infections, with findings describing patterns where measurements of clinical cure status were reported in the observed populations. However, major trials often excluded severe or complicated infections, and limited information is available in the research context of highly resistant bacterial strains.


Evidence for Use in Genitourinary Tract Infections (UTIs)

The evidence base for Cephalexin in certain infections of the urinary tract, including acute prostatitis, includes findings from historical clinical trials and prospective comparative studies. Authoritative sources document a consistent history of use. Research was evaluated for outcomes related to bacteriological clearance, which monitors patterns related to eliminating bacteria. However, the evidence relies on older data for establishing its foundational role, and studies must continually account for evolving microbial resistance patterns.


Evidence for Use in Acute Otitis Media

Research exploring the role of Cephalexin in Acute Otitis Media (AOM) includes findings from Randomized Comparative Trials in pediatric populations. The main outcomes monitored included clinical response and clinical failure. Research describes the medicine was evaluated in trials as an option for patients with known or suspected penicillin allergy. Studies monitored differences in clinical response when the AOM was caused by specific pathogens like Haemophilus influenzae. The evidence level for this indication is often described as moderate.


Long-Term Studies and Follow-up Durations

The majority of published clinical trials focus on short-term outcomes relevant to acute infections. The follow-up durations were limited, typically lasting only 7 to 14 days after treatment initiation, which was typically used to assess the short-term status. Consequently, the long-term effects are not fully established, and there is limited information regarding the durability of the response beyond the immediate post-treatment window.


What Is Still Uncertain About Cephalexin

While substantial, the body of evidence contains key limitations. The evidence quality varies across studies due to the reliance on older trial designs for certain indications. A significant gap exists in research that fully accounts for the current, rapidly changing landscape of antimicrobial resistance. Comparative evidence against newer antibiotics is often lacking. Overall, research provides context but not individual predictions, and the findings describe group patterns.

Key Studies & References

  1. Cephalexin Drug Label Information (Approved Indications, FDA)
  2. Clinical Practice Guideline for the Treatment of Skin and Soft Tissue Infections (Infectious Diseases Society of America - IDSA)

Frequently Asked Questions (FAQ)

Common questions about Cephalexin (FAQ)


Q: What is the difference between Cephalexin and Amoxicillin?

A: Cephalexin and Amoxicillin belong to the larger family of β-lactam antibiotics. However, official information clarifies that Cephalexin is classified as a first-generation cephalosporin, while Amoxicillin is classified as a penicillin antibiotic. This distinction relates to their chemical structure and the range of bacteria they are active against.

Q: How quickly does Cephalexin usually start to work?

A: According to the official pharmacokinetics (how the body handles the drug) information, Cephalexin is rapidly absorbed after being taken by mouth. Peak drug levels in the bloodstream typically occur about one hour after a dose. The antibacterial effects are generally expected to follow this absorption period, though the timeline for clinical improvement varies by individual.

Q: What is the typical length of treatment with Cephalexin?

A: Regulatory documents state that the course of treatment is generally between 7 to 14 days. For infections caused by β-hemolytic streptococci, which is a specific type of bacteria, a minimum duration of 10 days is required as part of the established treatment regimen to address the infection.

Q: Can Cephalexin cause severe diarrhea, and what should I watch for?

A: Diarrhea is a Common adverse reaction documented in official labeling. Additionally, Cephalexin and other antibiotics have been associated with a more serious condition called Pseudomembranous Colitis (C. difficile-associated diarrhea), which can occur during or even after treatment. This risk is highlighted in the drug's safety information.

Q: Does Cephalexin interact with oral contraceptive pills?

A: Official drug labels do not specifically list an interaction between Cephalexin and hormonal contraceptives. General guidelines for this class of antibiotic often state that they do not typically interfere with the effectiveness of birth control pills and are not typically associated with requiring additional contraceptive precautions.

Q: Which prescription medicines are known to interact with Cephalexin?

A: Regulatory documents specifically list two drug-drug interactions. Probenecid can increase and prolong the levels of Cephalexin in the body. Co-administration also significantly increases the systemic exposure of the anti-diabetes medicine Metformin.

Q: Is Cephalexin considered safe for use during pregnancy?

A: Official regulatory labeling classifies Cephalexin as Pregnancy Category B. Its use during pregnancy is described as limited to situations where the drug is clearly needed by the patient. This evaluation is typically conducted by a healthcare provider.

Q: What is the information regarding Cephalexin use while breastfeeding?

A: Official information indicates that Cephalexin is excreted in human milk, and therefore caution should be exercised when the medicine is given to a nursing mother. Regulatory data reports that low levels of the drug are present in the milk.

Q: Can over-the-counter pain relievers be taken at the same time as Cephalexin?

A: Official regulatory labels do not document specific interactions between Cephalexin and common over-the-counter pain relievers like ibuprofen or acetaminophen. Decisions about combining any medicines should be discussed with a healthcare professional.

Q: Is it better to take Cephalexin with food or on an empty stomach?

A: Cephalexin is described as acid stable, meaning it can reliably be absorbed in the stomach regardless of food intake. Regulatory instructions state that the medicine may be administered without regard to meals.

Q: Does Cephalexin increase the risk of bleeding in people taking blood thinners like warfarin?

A: Regulatory labels for Cephalexin do not specifically list the blood thinner Warfarin as an interacting substance. However, official information notes that certain antibiotics in the cephalosporin class have been reported to potentially alter the body's clotting ability.

Q: What are the general research themes regarding the effectiveness of Cephalexin?

A: Research themes described in the official product information include measuring clinical cure and microbiological cure for uncomplicated Skin and Skin Structure Infections. Studies also examine outcomes related to bacteriological clearance for Genitourinary Tract Infections and clinical response for Acute Otitis Media in children.

Q: What is the connection between Cephalexin and a positive direct Coombs' test?

A: Cephalosporins, including Cephalexin, may be associated with a positive direct Coombs' test result. This is a laboratory test related to the immune system's effect on red blood cells. The drug is also associated with rare cases of Hemolytic Anemia, a condition affecting red blood cells.

Q: What should I do if my symptoms do not improve after a few days of taking Cephalexin?

A: Regulatory-aligned information advises that if symptoms do not improve within a few days of starting treatment, or if the symptoms become worse, consultation with a healthcare provider is generally recommended. This step can help to determine the appropriate course of action.

Q: Is a mild rash a common reaction to Cephalexin?

A: Yes, Rash is categorized in official documents as a Common adverse reaction to Cephalexin. However, official labeling also highlights the rare risk of severe skin reactions like Stevens-Johnson Syndrome. The reporting of any changes to the skin is described as important for safety monitoring.

Q: Can I consume alcohol while taking a course of Cephalexin?

A: Official regulatory labeling do not list a specific drug interaction with alcohol. However, alcohol consumption may potentially worsen some of the common side effects of Cephalexin, such as nausea or dizziness.

Q: Is there a known interaction between Cephalexin and zinc supplements or multivitamins containing zinc?

A: Drug-aligned guidance notes that taking Cephalexin at the same time as supplements that contain zinc is generally not recommended. This is because zinc may reduce the amount of Cephalexin that is absorbed into the body, potentially affecting its effectiveness.

Q: Are there special considerations for children taking the liquid form of Cephalexin?

A: Special administration notes advise that the liquid suspension must be shaken well before each use and measured accurately with a calibrated device. After the medicine is prepared, any unused portion must be discarded after 14 days, even if it has been stored properly in the refrigerator.

Q: Can Cephalexin cause or contribute to a yeast infection?

A: Official information for this class of antibiotics often warns that their use can result in the overgrowth of non-susceptible organisms. This process, sometimes called superinfection, can include fungal overgrowth, which is commonly known as a yeast infection.

Q: What is the risk of antibiotic resistance when taking Cephalexin?

A: Official guidance emphasizes that Cephalexin should only be used to treat infections strongly suspected to be caused by susceptible bacteria. This practice helps to reduce the development of drug-resistant bacteria and maintain the drug's effectiveness.

Q: Does Cephalexin have any effect on driving or operating machinery?

A: Official labels do not contain a specific warning regarding driving. However, documented rare side effects such as dizziness or confusion may potentially affect the ability to drive or operate machinery.

Q: Does Cephalexin typically cause tiredness or dizziness?

A: In official regulatory documents, neither tiredness nor dizziness are listed in the Common or Uncommon frequency categories of side effects. This suggests they are not typical reactions, though individual experiences may vary.

Q: What happens if a child spits out a dose of Cephalexin liquid suspension?

A: Authoritative guidance suggests that if a child is sick or vomits less than 30 minutes after a dose, the same dose is generally repeated. If the child is sick more than 30 minutes after taking the medicine, one should wait until the time of the next normal dose.

Q: Are there any long-term side effects associated with Cephalexin use?

A: The majority of published clinical trials focus on short-term outcomes relevant to treating acute infections. Research evidence sections state that long-term effects are not fully established because the follow-up durations of these studies were generally limited to just a few weeks after treatment.

Q: Is there information on Cephalexin's effect on mental state, such as agitation or confusion?

A: Though rare, neurological effects have been documented in the drug's safety profile. Official labeling mentions the potential for seizures in certain circumstances. Other effects on the central nervous system may be associated with cephalosporin use.

Q: Has there been research on Cephalexin's efficacy for bone or joint infections?

A: While not a primary listed indication, research studies have been conducted to examine Cephalexin for the treatment of musculoskeletal (MSK) infections, which is the medical term for infections involving the bones and joints, often investigated in pediatric populations.

Q: Why is it important for a doctor to know if I have diabetes while taking Cephalexin?

A: It is important because of two documented facts: Cephalexin is known to interact with the anti-diabetes medicine Metformin, increasing its systemic exposure. Additionally, Cephalexin may cause a false-positive reaction for glucose in certain types of urine tests used by people with diabetes.

Q: What is the risk of an infection returning if Cephalexin is stopped too soon?

A: Regulatory instructions emphasize that the full prescribed course must be completed to eradicate the infection and minimize resistance. Stopping treatment too soon may increase the risk of bacterial survival, potentially leading to a return or relapse of the infection.

How should Cephalexin be stored and disposed of?

Storage Conditions

Formulation Required Storage Condition Stability Constraint
Capsules & Tablets Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) Protect from excessive heat, moisture, and light.
Oral Suspension Refrigerate after reconstitution (do not freeze). Discard any unused portion after 14 days.

All forms of Cephalexin must be kept in a closed container and stored securely out of the reach of children. The solid forms should be stored in the container they came in and protected from light.

Disposal Instructions

Regulatory guidance directs that expired or unused Cephalexin must not be kept. Patients should consult a healthcare professional or follow local take-back programs for proper disposal. Cephalexin is not on the U.S. FDA's flush list for medicines recommended to be discarded via the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cephalexin found in:

A-Z Index: